erbicinumab

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Nameerbicinumab
Drug Alias NameErbicinanti-HER2 bi-specific mAbs (Immune Pharmaceuticals/Weizmann Institute)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragmentBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human +[4] 
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsSolid tumoursHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesIsrael
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesImmune Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesWeizmann Institute Of ScienceImmune Pharmaceuticals IncBiotecnol Ltd
Active IndicationsN/A
Inactive IndicationsSolid tumoursHematologic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A